Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209129
From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
S100A9/S100A8 (calprotectin), a member of the S100 protein family, has been shown to play a pivotal role in innate immunity activation. Calprotectin plays a critical role in the pathogenesis of rheumatoid arthritis (RA), as it triggers chemotaxis, phagocyte migration and modulation of neutrophils and macrophages. Higher calprotectin levels have been found in synovial fluid, plasma, and serum from RA patients. Recent studies have demonstrated better correlations between serum or plasma calprotectin and composite inflammatory disease activity indexes than c-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR). Calprotectin serum levels decreased after treatment, independently of the DMARD type or strategy. Calprotectin has shown the strongest correlations with other sensitive techniques to detect inflammation, such as ultrasound. Calprotectin independently predicts radiographic progression. However, its value as a biomarker of treatment response and flare after tapering is unclear. This update reviews the current understanding of calprotectin in RA and discusses possible applications as a biomarker in clinical practice.
Matèries
Matèries (anglès)
Citació
Citació
INCIARTE MUNDO, José, FRADE SOSA, Beatriz, SANMARTÍ SALA, Raimon. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. _Frontiers In Immunology_. 2022. Vol. 13, núm. 1001025. [consulta: 25 de febrer de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/209129]